Home > Healthcare > Medical Devices > Therapeutic Devices > U.S. Intrauterine Devices Market

U.S. Intrauterine Devices Market Trends

Report ID: GMI2895
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

U.S. Intrauterine Devices Market Trends

The U.S. IUDs industry has seen several technological advancements and ongoing studies that are enhancing the safety, effectiveness, and user experience of IUDs.

Research and development efforts are focused on increasing the duration of effectiveness of hormonal IUDs. The latest IUDs can now offer protection for up to 7 years, compared to the previous standard of 3-5 years.
Additionally, some of the latest hormonal IUDs allow for adjustable hormone release levels, catering to individual needs and minimizing side effects. This customization helps in managing conditions such as heavy menstrual bleeding more effectively.
Moreover, research is ongoing to develop IUDs using alternative hormones to levonorgestrel, providing more options for women who may have sensitivities or adverse reactions to certain hormones. In recent years, the FDA has approved several new IUDs that incorporate these technological advancements. For example, in 2020, the FDA approved a lower-dose levonorgestrel-releasing IUD that provides effective contraception for up to 5 years.
Numerous clinical trials are ongoing in the U.S. to test the efficacy and safety of next-generation IUDs. These trials are crucial in bringing innovative products to market and gaining user trust.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. intrauterine devices industry size was worth USD 1.4 billion in 2023 and will grow at 9.5% CAGR between 2024 and 2032 due to increasing awareness and acceptance of long-term, reversible contraceptive methods.

U.S. intrauterine devices market from the hospital segment recorded 49% share in 2023, driven by the extensive resources and specialized care available in these facilities.

South Atlantic U.S. intrauterine devices industry captured USD 275.5 million in 2023, attributed to large population, growing healthcare access, and increasing awareness of reproductive health.

Prominent players operating in the U.S. intrauterine devices industry are Allergan (AbbVie Inc.), Bayer AG, CooperSurgical Inc., Durbin, Meril Life Sciences Pvt. Ltd., Mylan N.V. (Viatris), Pregna International Ltd., and SMB Corporation of India, among others.